FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520996611> ?p ?o ?g. }

• W2520996611 endingPage "1408" @default.
• W2520996611 startingPage "1399" @default.
• W2520996611 abstract "BackgroundDespite the existence of effective prevention and treatment interventions, hepatitis B virus (HBV) infection continues to cause nearly 1 million deaths each year. WHO aspires to global control and elimination of HBV infection. We aimed to evaluate the potential impact of public health interventions against HBV, propose targets for reducing incidence and mortality, and identify the key developments required to achieve them.MethodsWe developed a simulation model of the global HBV epidemic, incorporating data on the natural history of HBV, prevalence, mortality, vaccine coverage, treatment dynamics, and demographics. We estimate the impact of current interventions and scaling up of existing interventions for prevention of infection and introducing wide-scale population screening and treatment interventions on the worldwide epidemic.FindingsVaccination of infants and neonates is already driving a large decrease in new infections; vaccination has already prevented 210 million new chronic infections by 2015 and will have averted 1·1 million deaths by 2030. However, without scale-up of existing interventions, our model showed that there will be a cumulative 63 million new cases of chronic infection and 17 million HBV-related deaths between 2015 and 2030 because of ongoing transmission in some regions and poor access to treatment for people already infected. A target of a 90% reduction in new chronic infections and 65% reduction in mortality could be achieved by scaling up the coverage of infant vaccination (to 90% of infants), birth-dose vaccination (to 80% of neonates), use of peripartum antivirals (to 80% of hepatitis B e antigen-positive mothers), and population-wide testing and treatment (to 80% of eligible people). These interventions would avert 7·3 million deaths between 2015 and 2030, including 1·5 million cases of cancer deaths. An elimination threshold for incidence of new chronic infections would be reached by 2090 worldwide. The annual cost would peak at US$7·5 billion worldwide ($3·4 billion in low-income and lower-middle-income countries), but decrease rapidly and this would be accelerated if a cure is developed.InterpretationScale-up of vaccination coverage, innovations in scalable options for prevention of mother-to-child transmission, and ambitious population-wide testing and treatment are needed to eliminate HBV as a major public health threat. Achievement of these targets could make a major contribution to one of the Sustainable Development Goals of combating hepatitis.FundingMedical Research Council. Despite the existence of effective prevention and treatment interventions, hepatitis B virus (HBV) infection continues to cause nearly 1 million deaths each year. WHO aspires to global control and elimination of HBV infection. We aimed to evaluate the potential impact of public health interventions against HBV, propose targets for reducing incidence and mortality, and identify the key developments required to achieve them. We developed a simulation model of the global HBV epidemic, incorporating data on the natural history of HBV, prevalence, mortality, vaccine coverage, treatment dynamics, and demographics. We estimate the impact of current interventions and scaling up of existing interventions for prevention of infection and introducing wide-scale population screening and treatment interventions on the worldwide epidemic. Vaccination of infants and neonates is already driving a large decrease in new infections; vaccination has already prevented 210 million new chronic infections by 2015 and will have averted 1·1 million deaths by 2030. However, without scale-up of existing interventions, our model showed that there will be a cumulative 63 million new cases of chronic infection and 17 million HBV-related deaths between 2015 and 2030 because of ongoing transmission in some regions and poor access to treatment for people already infected. A target of a 90% reduction in new chronic infections and 65% reduction in mortality could be achieved by scaling up the coverage of infant vaccination (to 90% of infants), birth-dose vaccination (to 80% of neonates), use of peripartum antivirals (to 80% of hepatitis B e antigen-positive mothers), and population-wide testing and treatment (to 80% of eligible people). These interventions would avert 7·3 million deaths between 2015 and 2030, including 1·5 million cases of cancer deaths. An elimination threshold for incidence of new chronic infections would be reached by 2090 worldwide. The annual cost would peak at US$7·5 billion worldwide ($3·4 billion in low-income and lower-middle-income countries), but decrease rapidly and this would be accelerated if a cure is developed. Scale-up of vaccination coverage, innovations in scalable options for prevention of mother-to-child transmission, and ambitious population-wide testing and treatment are needed to eliminate HBV as a major public health threat. Achievement of these targets could make a major contribution to one of the Sustainable Development Goals of combating hepatitis." @default.
• W2520996611 created "2016-09-23" @default.
• W2520996611 creator A5023606749 @default.
• W2520996611 creator A5025322446 @default.
• W2520996611 creator A5031275760 @default.
• W2520996611 creator A5032374292 @default.
• W2520996611 creator A5049874690 @default.
• W2520996611 creator A5071473618 @default.
• W2520996611 creator A5083161394 @default.
• W2520996611 date "2016-12-01" @default.
• W2520996611 modified "2023-10-11" @default.
• W2520996611 title "Requirements for global elimination of hepatitis B: a modelling study" @default.
• W2520996611 cites W1489762401 @default.
• W2520996611 cites W1560139616 @default.
• W2520996611 cites W1799522345 @default.
• W2520996611 cites W1903855464 @default.
• W2520996611 cites W1924400606 @default.
• W2520996611 cites W1930478503 @default.
• W2520996611 cites W1936783363 @default.
• W2520996611 cites W1982127069 @default.
• W2520996611 cites W1995318027 @default.
• W2520996611 cites W2004054613 @default.
• W2520996611 cites W2034561831 @default.
• W2520996611 cites W2053113035 @default.
• W2520996611 cites W2056704058 @default.
• W2520996611 cites W2067109440 @default.
• W2520996611 cites W2077496122 @default.
• W2520996611 cites W2088305891 @default.
• W2520996611 cites W2090093073 @default.
• W2520996611 cites W2110533619 @default.
• W2520996611 cites W2112195292 @default.
• W2520996611 cites W2121972870 @default.
• W2520996611 cites W2125849337 @default.
• W2520996611 cites W2130096933 @default.
• W2520996611 cites W2140706412 @default.
• W2520996611 cites W2142143280 @default.
• W2520996611 cites W2148216588 @default.
• W2520996611 cites W2156015715 @default.
• W2520996611 cites W2163274841 @default.
• W2520996611 cites W2168630917 @default.
• W2520996611 cites W2462340700 @default.
• W2520996611 cites W2475385134 @default.
• W2520996611 cites W2488426658 @default.
• W2520996611 cites W3030265267 @default.
• W2520996611 doi "https://doi.org/10.1016/s1473-3099(16)30204-3" @default.
• W2520996611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27638356" @default.
• W2520996611 hasPublicationYear "2016" @default.
• W2520996611 type Work @default.
• W2520996611 sameAs 2520996611 @default.
• W2520996611 citedByCount "264" @default.
• W2520996611 countsByYear W25209966112016 @default.
• W2520996611 countsByYear W25209966112017 @default.
• W2520996611 countsByYear W25209966112018 @default.
• W2520996611 countsByYear W25209966112019 @default.
• W2520996611 countsByYear W25209966112020 @default.
• W2520996611 countsByYear W25209966112021 @default.
• W2520996611 countsByYear W25209966112022 @default.
• W2520996611 countsByYear W25209966112023 @default.
• W2520996611 crossrefType "journal-article" @default.
• W2520996611 hasAuthorship W2520996611A5023606749 @default.
• W2520996611 hasAuthorship W2520996611A5025322446 @default.
• W2520996611 hasAuthorship W2520996611A5031275760 @default.
• W2520996611 hasAuthorship W2520996611A5032374292 @default.
• W2520996611 hasAuthorship W2520996611A5049874690 @default.
• W2520996611 hasAuthorship W2520996611A5071473618 @default.
• W2520996611 hasAuthorship W2520996611A5083161394 @default.
• W2520996611 hasBestOaLocation W25209966111 @default.
• W2520996611 hasConcept C118552586 @default.
• W2520996611 hasConcept C119599485 @default.
• W2520996611 hasConcept C120665830 @default.
• W2520996611 hasConcept C121332964 @default.
• W2520996611 hasConcept C127413603 @default.
• W2520996611 hasConcept C138816342 @default.
• W2520996611 hasConcept C159110408 @default.
• W2520996611 hasConcept C187212893 @default.
• W2520996611 hasConcept C203014093 @default.
• W2520996611 hasConcept C22070199 @default.
• W2520996611 hasConcept C2522874641 @default.
• W2520996611 hasConcept C27415008 @default.
• W2520996611 hasConcept C2777382497 @default.
• W2520996611 hasConcept C2780593183 @default.
• W2520996611 hasConcept C2908647359 @default.
• W2520996611 hasConcept C46578552 @default.
• W2520996611 hasConcept C61511704 @default.
• W2520996611 hasConcept C71924100 @default.
• W2520996611 hasConcept C761482 @default.
• W2520996611 hasConcept C99454951 @default.
• W2520996611 hasConceptScore W2520996611C118552586 @default.
• W2520996611 hasConceptScore W2520996611C119599485 @default.
• W2520996611 hasConceptScore W2520996611C120665830 @default.
• W2520996611 hasConceptScore W2520996611C121332964 @default.
• W2520996611 hasConceptScore W2520996611C127413603 @default.
• W2520996611 hasConceptScore W2520996611C138816342 @default.
• W2520996611 hasConceptScore W2520996611C159110408 @default.
• W2520996611 hasConceptScore W2520996611C187212893 @default.
• W2520996611 hasConceptScore W2520996611C203014093 @default.
• W2520996611 hasConceptScore W2520996611C22070199 @default.
• W2520996611 hasConceptScore W2520996611C2522874641 @default.

• next